GlassScriptPhysician profile
Grayce N Selig
NPI 1497242069
$1,738.19
in general payments reported to CMS, 2019-2025
14 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $150 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,196 · Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Food and Beverage | $541.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,331.84 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $78.12 | 2025 | Calquence, Tagrisso, Enhertu |
| Tempus Ai, INC | $62.42 | 2024 | |
| Pfizer INC. | $36.72 | 2025 | |
| Aveo Pharmaceuticals, INC. | $33.60 | 2025 | |
| Eisai INC. | $31.90 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $31.13 | 2025 | Opdualag |
| Puma Biotechnology, INC. | $27.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.04 | 2025 | |
| Glaxosmithkline, LLC. | $19.38 | 2024 | Jemperli, Zejula |
| Array Biopharma INC | $19.32 | 2025 | Braftovi, Lorbrena, Mektovi |
| Merck Sharp & Dohme LLC | $16.87 | 2025 | Keytruda, Keytruda Qlex |
| Janssen Biotech, INC. | $14.71 | 2025 | Erleada |
| Incyte Corporation | $13.82 | 2024 | Pemazyre, Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grayce Selig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.